Table 1.
Source of MSCs | Condition | Total number of clinical trials | Autologous | Allogeneic | ||
---|---|---|---|---|---|---|
BM-MSCs | Ischemia* | 28 | 21 | 8 | ||
Bone regeneration | 18, thereof 9 TE# | 14 | 3 | |||
Graft rejection | 12 | 4 | 9 | |||
Degenerative diseases§ | 12 | 9 | 2 | |||
Lung diseases† | 9 | 3 | 6 | |||
Multiple sclerosis | 9 | 9 | 0 | |||
Amyotrophic lateral sclerosis | 3 | 3 | 0 | |||
AT-MSCs | Ischemia* | 10 | 6 | 2 | ||
Degenerative diseases§ | 8 | 7 | 1 | |||
Crohn's disease | 3 | 1 | 2 | |||
Spinal cord injury | 2 | 2 | 0 | |||
Liver cirrhosis | 2 | 2 | 0 | |||
Multiple sclerosis | 2 | 2 | 0 | |||
Amyotrophic lateral sclerosis | 2 | 1 | 1 | |||
BM-MSCs | GvHD | 23 | 1 | 20 | ||
AT-MSCs | GvHD | 3 | 1 | 2 |
Including myocardial infarction, stroke, and critical limb ischemia.
Tissue engineering, e.g. MSCs seeded on bioceramic plates or immobilized in allogeneic bone prior to implantation.
e.g. osteoarthritis, degenerative disc disease.
e.g. emphysema, respiratory distress syndrome.